In September, AstraZeneca's subsidiary MedImmune gained approval for a live H1N1 Flumist vaccine. Further afield, Beijing-based Sinovac Biotech also received approval for an H1N1 vaccine from the ...
Also Read: Amgen/AstraZeneca’s Asthma Drug Tezspire Vs. Sanofi/Regeneron’s Blockbuster Dupixent – Analyst Gives His Pick WAYPOINT is a randomized, double-blind trial that evaluated the ...
Not too long ago, pharmaceutical giant Astrazeneca reached a £200bn valuation—one of only a few London-listed FTSE 100 companies to do so. The major milestone was a testament to CEO Pascal ...
AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...
AstraZeneca and Honeywell are developing MDIs that will use a new propellant called HFO-1234ze, which, according to the company, has 99.9% less Global Warming Potential (GWP) than existing ...
Background Because inactivated trivalent influenza vaccines (TIVs) contain 1 influenza B strain, whereas 2 lineages may co-circulate, B lineage mismatch is frequent. We assessed an inactivated ...
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...
AstraZeneca Pharma India Ltd., incorporated in the year 1979, is a Mid Cap company (having a market cap of Rs 18,267.00 Crore) operating in Pharmaceuticals sector. AstraZeneca Pharma India Ltd. key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback